This is a working overview of REV-ERB, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Themes of nature, pioneers, trappers, and traders played an important part in the early development of Canadian symbolism. Modern symbols emphasize the country's geography, northern climate, lifestyles, and the Canadianization of traditional European and Indigenous symbols. The use of the maple leaf as a symbol dates to the early 18th century in New France. The maple leaf is depicted on Canada's current and previous flags and on the arms of Canada. Canada's official tartan, known as the "maple leaf tartan", reflects the colours of the maple leaf through the seasons—green in the spring, gold in the early autumn, red at the first frost, and brown after falling. The arms of Canada are closely modelled after those of the United Kingdom, with French and distinctive Canadian elements replacing or added to those derived from the British version. Other prominent symbols include the national motto, "A mari usque ad mare" ("from sea to sea"), the sports of ice hockey and lacrosse, the beaver, Canada goose, common loon, Canadian horse, the Royal Canadian Mounted Police, the Canadian Rockies, and, more recently, the Indigenous totem pole and Inuksuk. Canadian cuisine items such as Canadian beer, maple syrup, Nanaimo bars, butter tarts, and the Quebec dishes of poutine and tourtière, alongside material items such as tuques, canoes and Hudson's Bay point blanket are considered as uniquely Canadian. Canadian coins feature many of these symbols: the loon on the $1 coin, the coat of arms on the 50¢ piece, and the beaver on the nickel.
== Disorders == The body's hemostasis system requires careful regulation in order to work properly. If the blood does not clot sufficiently, it may be due to bleeding disorders such as hemophilia or immune thrombocytopenia; this requires careful investigation. Over-active clotting can also cause problems; thrombosis, where blood clots form abnormally, can potentially cause embolisms, where blood clots break off and subsequently become lodged in a vein or artery. Hemostasis disorders can develop for many different reasons. They may be congenital, due to a deficiency or defect in an individual's platelets or clotting factors. A number of disorders can be acquired as well, such as in HELLP syndrome, which is due to pregnancy, or Hemolytic-uremic syndrome (HUS), which is due to E. coli toxins.
In September 1992, Austin formed a tag team known as the Hollywood Blonds with Brian Pillman, at the behest of lead booker Dusty Rhodes. Austin would later say that he was not excited about being placed into a tag team, as he was earmarked for a run with the WCW United States Heavyweight Championship with Harley Race as his manager. Initially billed under their individual personas, Pillman decided the pair needed their own finishing move, ring gear and team name, with traveling partner Scott Levy proposing the Hollywood Blonds, used in the 1970s by Buddy Roberts and Jerry Brown. At Halloween Havoc in October 1992, Austin (substituting for Terry Gordy) teamed with "Dr. Death" Steve Williams to wrestle Dustin Rhodes and Windham for the unified WCW and NWA World Tag Team Championship, wrestling to a 30-minute time limit draw. On March 27, 1993, the Hollywood Blonds won the unified NWA and WCW World Tag Team Championship by defeating Ricky Steamboat and Shane Douglas, and held the championship for five months. In the main event of Clash of the Champions XXIII in June 1993, the Blondes defended their championship against Ric Flair and Arn Anderson in a two-out-of-three-falls, where despite losing the first two falls, retained the championship as the second fall had been determined by a disqualification caused by Barry Windham. At Clash of the Champions XXIV In August 1993, Austin and Pillman were scheduled to defend their championship against Anderson and Paul Roma but a legitimately injured Pillman was replaced by Steven Regal, with whom Austin lost to Anderson and Roma.
Sources: en.wikipedia.org
Other powerful extensions to the dead-end elimination algorithm include the pairs elimination criterion, and the generalized dead-end elimination criterion. This algorithm has also been extended to handle continuous rotamers with provable guarantees. Although the Dead-end elimination algorithm runs in polynomial time on each iteration, it cannot guarantee convergence. If, after a certain number of iterations, the dead-end elimination algorithm does not prune any more rotamers, then either rotamers have to be merged or another search algorithm must be used to search the remaining search space. In such cases, the dead-end elimination acts as a pre-filtering algorithm to reduce the search space, while other algorithms, such as A*, Monte Carlo, Linear Programming, or FASTER are used to search the remaining search space.
In 2005, the FDA added a boxed warning concerning pediatric suicidal behavior to all antidepressants, including sertraline. In 2007, labeling was again changed to add a warning regarding suicidal behavior in young adults ages 18 to 24.
== Production Sites == IMA Life has four production sites, one located in the outskirts of Bologna, one in Calenzano near Florence, one in Tonawanda, NY (USA) and one in Beijing (China). Apart from its manufacturing plants, it has sales and service centers at Puerto Rico, Brazil, France, Italy, Ireland, China and Japan.
== As a drug target == EAAT2/GLT-1, being the most abundant subtype of glutamate transporter in the CNS, plays a key role in regulation of glutamate neurotransmission. Dysfunction of EAAT2 has been correlated with various pathologies such as traumatic brain injury, stroke, Amyotrophic lateral sclerosis (ALS), Alzheimer's disease, among others. Therefore, activators of the function or enhancers of the expression of EAAT2/GLT-1 could serve as a potential therapy for these conditions. Translational activators of EAAT2/GLT-1, such as ceftriaxone and LDN/OSU-0212320, have been described to have significant protective effects in animal models of ALS and epilepsy. In addition, pharmacological activators of the activity of EAAT2/GLT-1 have been explored for decades and are currently emerging as promising tools for neuroprotection, having potential advantages over expression activators. DL-TBOA, WAY-213,613, and dihydrokainic acid are known inhibitors of the protein, and function as excitotoxins. They can be considered a novel class of nerve agent toxins, inducing toxic levels of glutamate through transport inhibition in a manner analogous to the effect of sarin on cholinesterase. Antidotes for such a poisoning have never been formally tested for efficacy and are not readily available for medical use. Addiction to certain drugs (e.g., cocaine, heroin, alcohol, and nicotine) is correlated with a persistent reduction in the expression of EAAT2 in the nucleus accumbens (NAcc); the reduced expression of EAAT2 in this region is implicated in addictive drug-seeking behavior.
Sources: en.wikipedia.org
== External links == Hird v Chief Executive Officer of the Australian Sports Anti-Doping Authority (9 October 2014) [2014] FCA 1090 Hird v Chief Executive Officer of the Australian Sports Anti-Doping Authority (includes Summary) (30 January 2015) [2015] FCAFC 7 Hird v Chubb Insurance Company of Australia Ltd (3 May 2016) [2016] VSC 174 Hird's official coaching profile on Essendonfc.com.au Hird's past player's profile on Essendonfc.com.au James Hird's playing statistics from AFL Tables
The reality is that present computational methods are imperfect and provide, at best, only qualitatively accurate estimates of affinity. In practice, it requires several iterations of design, synthesis, and testing before an optimal drug is discovered. Computational methods have accelerated discovery by reducing the number of iterations required and have often provided novel structures. Computer-aided drug design may be used at any of the following stages of drug discovery:
== Pathogenicity == Rhizopus oryzae is one of the most common causes of a disease known as mucormycosis, characterized by growing hyphae within and surrounding blood vessels. The causal agents of mucormycosis may also produce toxins like agroclavine which is toxic to humans, sheep and cattle. This infection usually occurs in immunocompromised individuals but is rare. Common risk factors associated with primary cutaneous mucormycosis is ketoacidosis, neutropenia, acute lymphobloastic leukemia, lymphomas, systemic steroids, chemotherapy, and dialysis. Treatment includes amphotericin B, posaconazole, itraconazole, and fluconazole. The majority of the cases of infection are rhinocerebral infections. At the same time, it has been found in literature that R. oryzae can produce antibiotic activity on some bacteria. The pathogenicity towards plants is attributed to the presence of large number of carbohydrate digesting enzymes.
== Adverse effects == Common (4–10% frequency) side effects of prazosin include dizziness, headache, drowsiness, fatigue, weakness, palpitations, and nausea. Less frequent (1–4%) side effects include vomiting, diarrhea, constipation, edema, orthostatic hypotension, dyspnea, syncope, vertigo, depression, anxiety, nasal congestion, and rash. A very rare side effect of prazosin is priapism. One phenomenon associated with prazosin is known as the "first-dose response", in which the side effects of the drug—specifically orthostatic hypotension, dizziness, and drowsiness—are especially pronounced in the first dose. Orthostatic hypotension and syncope are associated with the body's poor ability to control blood pressure without active α-adrenergic receptors. The nasal congestion is exacerbated by changing body positions, because α1-adrenergic receptors also control nasal vascular blood flow and alpha blockers inhibit this, in the same way that alpha-adrenergic agonists have the opposite effect of being a decongestant.
== History == The agent was discovered at Aston University in Birmingham, England. Its preclinical activity was reported in 1987. It was approved for medical use in the European Union in January 1999, and in the United States in August 1999. The intravenous formulation was approved in the United States in February 2009. In 2023 the University Hospitals Coventry and Warwickshire NHS Trust came under scrutiny when the temozolomide overprescription incident was discovered. It was found that a consultant clinical oncologist had been perscribing temozolomide for much longer than the NHS recommended guideline of six months. One patient had been on the medication for 16 years.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.